Trials / Terminated
TerminatedNCT06042920
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Non-Pustular PalmoPlantar and Genital Psoriasis (Psoriatyk Special Sites)
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | Specified dose on specified days |
| DRUG | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2023-10-09
- Primary completion
- 2025-04-25
- Completion
- 2025-04-25
- First posted
- 2023-09-21
- Last updated
- 2026-04-17
- Results posted
- 2026-04-17
Locations
31 sites across 3 countries: United States, Argentina, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06042920. Inclusion in this directory is not an endorsement.